Affinity Biopharma
Latest round
- Series B
Last raised
- Sep 2025
Total raised
- $98M
Investors
- 16
About Affinity Biopharma
Established in 2012 and based in Shanghai, China, Affinity Biopharma, together with its main subsidiary Qinhely, operates as a clinical biomedical company that focuses on anticancer drugs development. The company cooperated with I-MAB Biopharma. The company held the QHL-108 phase II/III clinical trial national kick-off meeting in September 2021. Chen Liu, the founder of the company, served as a professor of the department of immunology at Scripps research institute in the USA. The company's QHL-236 Legutaxel clinical trial application passed in April 2022. The company develops tumour microenvironment-activated (TMEA) platform technology. Its platforms are divided into two series, which include the small molecule platform and the macromolecule platform. The small molecule platform includes TMEA-SMDC platform. The macromolecule platform includes TMEAbody® platform, TMEAkine® platform, TMEA-ICE® platform and ADC platform. In addition, the company engages in pipeline R&D, which includes coupled small-molecule drugs and coupled biologics. Its listed product is Gelsooth oral antibacterial gel. Affinity Biopharma generates revenue by developing tumor microenvironment-responsive drug development platform.
Who invested in Affinity Biopharma
16 investors across 5 rounds
See all investors in Affinity Biopharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Affinity Biopharma
Who invested in Affinity Biopharma?
Affinity Biopharma has 16 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Affinity Biopharma raised?
Affinity Biopharma has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Affinity Biopharma last raise money?
Affinity Biopharma's most recent round on record is a Series B, in Sep 2025.
What does Affinity Biopharma do?
Established in 2012 and based in Shanghai, China, Affinity Biopharma, together with its main subsidiary Qinhely, operates as a clinical biomedical company that focuses on anticancer drugs development.
Where is Affinity Biopharma headquartered?
Affinity Biopharma is headquartered in Shanghai, China.
Which VCs invest in companies like Affinity Biopharma?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Affinity Biopharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Affinity Biopharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.